Verschoor E J, Willemse M J, Stam J G, van Vliet A L, Pouwels H, Chalmers S K, Horzinek M C, Sondermeijer P J, Hesselink W, de Ronde A
Virology Unit, Institute of Infectious Diseases and Immunology, Veterinary Faculty, University Utrecht, The Netherlands.
Vaccine. 1996 Mar;14(4):285-9. doi: 10.1016/0264-410x(95)00205-f.
Subunit vaccines prepared against feline immunodeficiency virus (FIV) infection were evaluated in two trials. First, cats were immunized with bacterial expression products of an envelope fragment that contained the V3 neutralization domain of the FIV surface protein fused to either galactokinase (K-SU3) or glutathione-S-transferase (G-SU3). Quantitative and qualitative differences in the humoral immune response were observed with three adjuvants of which Quil A was the best in terms of total and virus neutralizing antibody. Notwithstanding the responses induced, 19 of 20 immunized cats did not resist challenge and became infected. To determine whether priming with a live viral vector would confer protection, cats were inoculated oronasally and subcutaneously with a feline herpesvirus (FHV) mutant expressing the FIV env gene; two booster immunizations followed using the K-SU3 product in either Quil A or a mineral oill Al(OH)3 adjuvant. FIV-specific antibody responses were only weak, and the vaccinates did not withstand challenge with a low dose of homologous virus.
针对猫免疫缺陷病毒(FIV)感染制备的亚单位疫苗在两项试验中进行了评估。首先,用包膜片段的细菌表达产物对猫进行免疫,该包膜片段包含与半乳糖激酶(K-SU3)或谷胱甘肽-S-转移酶(G-SU3)融合的FIV表面蛋白的V3中和结构域。使用三种佐剂观察到体液免疫反应的定量和定性差异,其中Quil A在总抗体和病毒中和抗体方面表现最佳。尽管诱导了免疫反应,但20只免疫猫中有19只未能抵抗攻击并被感染。为了确定用活病毒载体进行初免是否能提供保护,给猫经口鼻腔和皮下接种表达FIV env基因的猫疱疹病毒(FHV)突变体;随后使用Quil A或矿物油Al(OH)3佐剂中的K-SU3产品进行两次加强免疫。FIV特异性抗体反应仅很微弱,接种疫苗的猫无法抵抗低剂量同源病毒的攻击。